0000000000476572

AUTHOR

Jyrki P. Kukkonen

0000-0002-6989-1564

showing 5 related works from this author

Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1.

2005

The G protein coupling characteristics of a flag epitope-tagged orexin receptor type 1 (OX1R) was investigated in HEK293 cells. Immunoprecipitation of the OX1R and immunoblotting revealed interactions with Gq/G11 proteins as well as with Gs and Gi proteins. Stimulation with orexin-A did not affect the ability of the OX1R to coprecipitate Gq/G11 proteins, but it robustly elevated the intracellular concentration of Ca2+, [Ca2+]i. No changes in cAMP levels could be detected upon receptor stimulation. To get further insight into the functional correlation of G protein activation and Ca2+ signalling, we used baculovirus transduction to express chimeric G proteins, containing the Galphas protein …

AgonistReceptors Neuropeptidemedicine.drug_classG proteinBiologyKidneyBiochemistryCell LineReceptors G-Protein-CoupledGTP-binding protein regulatorsGTP-Binding ProteinsOrexin ReceptorsTransduction GeneticMuscarinic acetylcholine receptormedicineCyclic AMPHumansCalcium SignalingPharmacologyReceptor Muscarinic M3Neurotransmitter AgentsOrexinsDose-Response Relationship DrugNeuropeptidesIntracellular Signaling Peptides and ProteinsMuscarinic acetylcholine receptor M3Fusion proteinOrexin receptorCell biologyBiochemistryCalciumSignal transductionBaculoviridaeSignal TransductionBiochemical pharmacology
researchProduct

The Concise Guide To Pharmacology 2021/22: G Protein-Coupled Receptors

2021

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will s…

RMCytoplasmic and NuclearComputer scienceDatabases PharmaceuticalHumans; Ion Channels; Ligands; Receptors Cytoplasmic and Nuclear; Receptors G-Protein-Coupled; Databases Pharmaceutical; PharmacologyReceptors Cytoplasmic and NuclearIN-VITRO CHARACTERIZATIONPharmacologyLigandsIon ChannelsNORSlaw.inventionReceptors G-Protein-CoupledG-Protein-CoupledDatabases03 medical and health sciencesCALCIUM-SENSING RECEPTOR0302 clinical medicineDELTA-OPIOID RECEPTORlawSummary informationReceptorsHumansHISTAMINE H-3 RECEPTORFATTY-ACID RECEPTORMETABOTROPIC GLUTAMATE-RECEPTOR030304 developmental biologyG protein-coupled receptorPharmacologyGONADOTROPIN-RELEASING-HORMONE0303 health sciencesClinical pharmacologyFORMYL PEPTIDE RECEPTORMUSCARINIC ACETYLCHOLINE-RECEPTOR3. Good health317 Pharmacy030220 oncology & carcinogenesisPharmaceuticalNEGATIVE ALLOSTERIC MODULATORCatalytic receptors
researchProduct

Azulene as a biphenyl mimetic in orexin/hypocretin receptor agonists

2023

Azulene is a rare ring structure in drugs, and we investigated whether it could be used as a biphenyl mimetic in known orexin receptor agonist Nag 26, which is binding to both orexin receptors OX1 and OX2 with preference towards OX2. The most potent azulene-based compound was identified as an OX1 orexin receptor agonist (pEC50 = 5.79 +/- 0.07, maximum response = 81 +/- 8% (s.e.m. of five independent experiments) of the maximum response to orexin-A in Ca2+ elevation assay). However, the azulene ring and the biphenyl scaffold are not identical in their spatial shape and electron distribution, and their derivatives may adopt different binding modes in the binding site. Peer reviewed

Orexin receptorSulfonamidesazuleneOrganic ChemistryClinical BiochemistryAgonistPharmaceutical ScienceMedicinal chemistryBiochemistrylääkekemia317 Pharmacymedicinal chemistrysulfonamidesDrug DiscoveryatsuleeniMolecular Medicine1182 Biochemistry cell and molecular biologyAzulene3111 BiomedicineagonistMolecular Biologyorexin receptor
researchProduct

Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus

2011

Increased levels of glutamate causing excitotoxic damage accompany neurological disorders such as ischemia/stroke, epilepsy and some neurodegenerative diseases. Cyclin-dependent kinase-5 (Cdk5) is important for synaptic plasticity and is deregulated in neurodegenerative diseases. However, the mechanisms by which kainic acid (KA)-induced excitotoxic damage involves Cdk5 in neuronal injury are not fully understood. In this work, we have thus studied involvement of Cdk5 in the KA-mediated degeneration of glutamatergic synapses in the rat hippocampus. KA induced degeneration of mossy fiber synapses and decreased glutamate receptor (GluR)6/7 and post-synaptic density protein 95 (PSD95) levels in…

0303 health sciencesKainic acidGeneral NeuroscienceCyclin-dependent kinase 5ExcitotoxicityGlutamate receptorBiologyHippocampal formationmedicine.disease_cause3. Good healthCell biology03 medical and health sciencesGlutamatergicchemistry.chemical_compound0302 clinical medicinenervous systemchemistrySynaptic plasticitymedicineReceptorNeuroscience030217 neurology & neurosurgery030304 developmental biologyEuropean Journal of Neuroscience
researchProduct

Origin of the prolactin-releasing hormone (PRLH) receptors: evidence of coevolution between PRLH and a redundant neuropeptide Y receptor during verte…

2004

We present seven new vertebrate homologs of the prolactin-releasing hormone receptor (PRLHR) and show that these are found as two separate subtypes, PRLHR1 and PRLHR2. Analysis of a number of vertebrate sequences using phylogeny, pharmacology, and paralogon analysis indicates that the PRLHRs are likely to share a common ancestry with the neuropeptide Y (NPY) receptors. Moreover, a micromolar level of NPY was able to bind and inhibit completely the PRLH-evoked response in PRLHR1-expressing cells. We suggest that an ancestral PRLH peptide started coevolving with a redundant NPY binding receptor, which then became PRLHR, approximately 500 million years ago. The PRLHR1 subtype was shown to have…

Prolactin-releasing hormoneGeneticsBase SequenceMolecular Sequence DataBiologyNeuropeptide Y receptorProlactinReceptors G-Protein-CoupledReceptors Neuropeptide YEvolution MolecularPhylogeneticsMolecular evolutionHormone receptorGene DuplicationGene duplicationVertebratesGeneticsAnimalsHumansReceptorPhylogenyGenomics
researchProduct